Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mucocutaneous Lymph Node Syndrome | 27 | 2024 | 538 | 7.170 |
Why?
|
Systemic Inflammatory Response Syndrome | 26 | 2024 | 621 | 4.100 |
Why?
|
Immunoglobulins, Intravenous | 17 | 2024 | 667 | 2.800 |
Why?
|
Coronary Aneurysm | 9 | 2024 | 234 | 2.450 |
Why?
|
Lupus Erythematosus, Systemic | 13 | 2024 | 2156 | 2.050 |
Why?
|
Rheumatology | 8 | 2023 | 619 | 1.320 |
Why?
|
Glucocorticoids | 11 | 2024 | 2158 | 1.160 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 5 | 2023 | 299 | 1.120 |
Why?
|
Macrophage Activation Syndrome | 6 | 2024 | 124 | 0.910 |
Why?
|
Immunomodulation | 4 | 2023 | 548 | 0.750 |
Why?
|
Child | 64 | 2024 | 80668 | 0.740 |
Why?
|
Insurance | 1 | 2022 | 115 | 0.700 |
Why?
|
Antirheumatic Agents | 6 | 2022 | 1383 | 0.680 |
Why?
|
Anti-Inflammatory Agents | 4 | 2014 | 1805 | 0.610 |
Why?
|
Arthritis, Rheumatoid | 3 | 2023 | 3788 | 0.590 |
Why?
|
Delayed Diagnosis | 2 | 2021 | 454 | 0.580 |
Why?
|
Critical Pathways | 1 | 2021 | 475 | 0.570 |
Why?
|
Risk Adjustment | 1 | 2021 | 597 | 0.560 |
Why?
|
Child, Preschool | 33 | 2024 | 42576 | 0.510 |
Why?
|
Connective Tissue Diseases | 3 | 2023 | 285 | 0.500 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2234 | 0.480 |
Why?
|
Rheumatic Diseases | 4 | 2024 | 656 | 0.470 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1884 | 0.470 |
Why?
|
Fever | 4 | 2023 | 1607 | 0.470 |
Why?
|
Hyperglycemia | 1 | 2022 | 1389 | 0.440 |
Why?
|
Vaccines | 1 | 2022 | 842 | 0.430 |
Why?
|
Injections, Intra-Articular | 1 | 2014 | 284 | 0.410 |
Why?
|
Infant | 23 | 2024 | 36460 | 0.400 |
Why?
|
Pneumonia, Viral | 4 | 2022 | 3231 | 0.390 |
Why?
|
Adolescent | 35 | 2024 | 88898 | 0.380 |
Why?
|
Musculoskeletal Diseases | 2 | 2023 | 598 | 0.380 |
Why?
|
Humans | 94 | 2024 | 766432 | 0.370 |
Why?
|
Prednisolone | 1 | 2012 | 326 | 0.360 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2332 | 0.360 |
Why?
|
Echocardiography | 3 | 2019 | 5030 | 0.360 |
Why?
|
Coronary Vessel Anomalies | 2 | 2020 | 308 | 0.350 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 2137 | 0.350 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2662 | 0.340 |
Why?
|
Decision Support Techniques | 2 | 2017 | 2007 | 0.340 |
Why?
|
Pandemics | 5 | 2024 | 8729 | 0.330 |
Why?
|
Kidney Failure, Chronic | 1 | 2022 | 2505 | 0.330 |
Why?
|
Retrospective Studies | 26 | 2024 | 81588 | 0.330 |
Why?
|
Pediatrics | 3 | 2021 | 3613 | 0.320 |
Why?
|
Health Status Disparities | 4 | 2024 | 1876 | 0.320 |
Why?
|
Immunoglobulins | 1 | 2012 | 853 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3109 | 0.300 |
Why?
|
Coronary Vessels | 2 | 2017 | 3094 | 0.290 |
Why?
|
Interferon Type I | 2 | 2023 | 568 | 0.290 |
Why?
|
Young Adult | 14 | 2024 | 59928 | 0.260 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4348 | 0.250 |
Why?
|
Male | 45 | 2024 | 363975 | 0.250 |
Why?
|
Female | 48 | 2024 | 396354 | 0.250 |
Why?
|
Mevalonate Kinase Deficiency | 1 | 2023 | 19 | 0.220 |
Why?
|
Chest Pain | 1 | 2010 | 1100 | 0.220 |
Why?
|
Hospitals, Pediatric | 3 | 2024 | 1851 | 0.220 |
Why?
|
Drug Therapy, Combination | 5 | 2021 | 6306 | 0.210 |
Why?
|
Sweet Syndrome | 1 | 2023 | 56 | 0.210 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 9243 | 0.210 |
Why?
|
Meningitis, Aseptic | 1 | 2023 | 59 | 0.210 |
Why?
|
Diagnosis, Differential | 9 | 2021 | 12979 | 0.210 |
Why?
|
Hospitalization | 5 | 2021 | 10812 | 0.200 |
Why?
|
Immunosuppressive Agents | 5 | 2023 | 4215 | 0.200 |
Why?
|
Prednisone | 2 | 2024 | 1566 | 0.190 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 253 | 0.190 |
Why?
|
Boston | 5 | 2024 | 9333 | 0.190 |
Why?
|
Interleukin-18 | 2 | 2020 | 251 | 0.190 |
Why?
|
Anxiety | 1 | 2016 | 4671 | 0.180 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7869 | 0.180 |
Why?
|
C-Reactive Protein | 7 | 2023 | 3852 | 0.180 |
Why?
|
Facial Hemiatrophy | 1 | 2020 | 24 | 0.180 |
Why?
|
Severity of Illness Index | 6 | 2024 | 15897 | 0.180 |
Why?
|
Child, Hospitalized | 1 | 2022 | 181 | 0.180 |
Why?
|
Paris | 1 | 2020 | 40 | 0.180 |
Why?
|
Age of Onset | 4 | 2024 | 3342 | 0.180 |
Why?
|
Agammaglobulinemia | 1 | 2022 | 173 | 0.180 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2021 | 104 | 0.170 |
Why?
|
Logistic Models | 3 | 2021 | 13276 | 0.170 |
Why?
|
Panniculitis | 1 | 2020 | 45 | 0.170 |
Why?
|
Pulmonary Alveolar Proteinosis | 1 | 2020 | 41 | 0.170 |
Why?
|
Registries | 4 | 2024 | 8344 | 0.170 |
Why?
|
Enteritis | 1 | 2021 | 162 | 0.170 |
Why?
|
Synovial Fluid | 1 | 2021 | 391 | 0.160 |
Why?
|
Socioeconomic Factors | 3 | 2021 | 7840 | 0.160 |
Why?
|
Erythema | 1 | 2020 | 261 | 0.160 |
Why?
|
France | 1 | 2020 | 495 | 0.160 |
Why?
|
Shock | 1 | 2021 | 316 | 0.160 |
Why?
|
Thrombophilia | 1 | 2021 | 308 | 0.150 |
Why?
|
Length of Stay | 4 | 2020 | 6490 | 0.150 |
Why?
|
Lung Diseases | 2 | 2023 | 1941 | 0.150 |
Why?
|
Atrioventricular Block | 1 | 2020 | 140 | 0.150 |
Why?
|
Eosinophilia | 1 | 2023 | 554 | 0.150 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.150 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 273 | 0.150 |
Why?
|
Stroke Volume | 5 | 2023 | 5583 | 0.150 |
Why?
|
Cell Polarity | 1 | 2021 | 637 | 0.150 |
Why?
|
Opportunistic Infections | 1 | 2021 | 376 | 0.150 |
Why?
|
Ventricular Function, Left | 4 | 2023 | 3919 | 0.150 |
Why?
|
Risk Factors | 14 | 2024 | 74828 | 0.140 |
Why?
|
Adenosine Deaminase | 1 | 2019 | 253 | 0.140 |
Why?
|
Syndrome | 2 | 2021 | 3271 | 0.140 |
Why?
|
Treatment Failure | 1 | 2023 | 2653 | 0.140 |
Why?
|
Aftercare | 1 | 2022 | 915 | 0.130 |
Why?
|
Depression | 1 | 2016 | 8229 | 0.130 |
Why?
|
Bacterial Infections | 2 | 2021 | 1390 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1142 | 0.130 |
Why?
|
Patient Transfer | 1 | 2022 | 789 | 0.120 |
Why?
|
Blood Coagulation | 1 | 2021 | 1162 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2020 | 1182 | 0.120 |
Why?
|
Treatment Outcome | 8 | 2023 | 65202 | 0.120 |
Why?
|
California | 1 | 2019 | 1435 | 0.120 |
Why?
|
Minority Groups | 1 | 2022 | 1208 | 0.120 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 938 | 0.120 |
Why?
|
Risk Assessment | 4 | 2021 | 24272 | 0.120 |
Why?
|
Focus Groups | 1 | 2021 | 1459 | 0.120 |
Why?
|
United States | 13 | 2024 | 72910 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1791 | 0.120 |
Why?
|
Infertility | 1 | 2021 | 655 | 0.110 |
Why?
|
Psoriasis | 1 | 2022 | 925 | 0.110 |
Why?
|
Prognosis | 3 | 2021 | 29922 | 0.110 |
Why?
|
Biological Products | 1 | 2023 | 948 | 0.110 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15390 | 0.110 |
Why?
|
North America | 1 | 2017 | 1287 | 0.110 |
Why?
|
Th17 Cells | 1 | 2020 | 788 | 0.110 |
Why?
|
Triamcinolone Acetonide | 1 | 2014 | 105 | 0.110 |
Why?
|
Japan | 1 | 2018 | 1417 | 0.110 |
Why?
|
Age Factors | 3 | 2021 | 18395 | 0.110 |
Why?
|
Singapore | 1 | 2014 | 299 | 0.110 |
Why?
|
Propensity Score | 1 | 2021 | 1972 | 0.110 |
Why?
|
Counseling | 1 | 2021 | 1552 | 0.110 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2023 | 3113 | 0.100 |
Why?
|
Pleurisy | 1 | 2013 | 54 | 0.100 |
Why?
|
Headache | 1 | 2020 | 1260 | 0.100 |
Why?
|
Evidence-Based Medicine | 3 | 2022 | 3690 | 0.100 |
Why?
|
Immunologic Factors | 2 | 2021 | 1594 | 0.100 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2019 | 1657 | 0.100 |
Why?
|
Patient Discharge | 2 | 2022 | 3465 | 0.100 |
Why?
|
Weight Gain | 1 | 2022 | 2356 | 0.100 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 6543 | 0.100 |
Why?
|
Laryngeal Diseases | 1 | 2015 | 248 | 0.100 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1732 | 0.100 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8536 | 0.090 |
Why?
|
Massachusetts | 2 | 2021 | 8885 | 0.090 |
Why?
|
Hepatomegaly | 1 | 2010 | 83 | 0.090 |
Why?
|
Decision Support Systems, Clinical | 1 | 2020 | 1178 | 0.090 |
Why?
|
Larynx | 1 | 2015 | 492 | 0.090 |
Why?
|
Interleukin-6 | 1 | 2020 | 3226 | 0.090 |
Why?
|
Respiratory Tract Diseases | 1 | 2016 | 744 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1659 | 0.090 |
Why?
|
Social Class | 1 | 2019 | 2006 | 0.090 |
Why?
|
Prospective Studies | 5 | 2023 | 54826 | 0.090 |
Why?
|
Aspirin | 2 | 2021 | 3134 | 0.090 |
Why?
|
Inflammation | 5 | 2023 | 10860 | 0.080 |
Why?
|
Qualitative Research | 1 | 2021 | 3138 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2021 | 2778 | 0.080 |
Why?
|
Sarcoidosis | 1 | 2015 | 534 | 0.080 |
Why?
|
Medication Adherence | 1 | 2021 | 2189 | 0.080 |
Why?
|
Disease Progression | 3 | 2023 | 13632 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3211 | 0.080 |
Why?
|
Pilot Projects | 1 | 2022 | 8720 | 0.080 |
Why?
|
Dilatation, Pathologic | 1 | 2010 | 527 | 0.080 |
Why?
|
Retreatment | 1 | 2010 | 596 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2432 | 0.080 |
Why?
|
Vaccination | 1 | 2021 | 3434 | 0.080 |
Why?
|
Cohort Studies | 3 | 2023 | 41703 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3403 | 0.080 |
Why?
|
Heart | 1 | 2021 | 4421 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2270 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2249 | 0.070 |
Why?
|
Adult | 11 | 2024 | 223253 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4712 | 0.070 |
Why?
|
Heart Diseases | 1 | 2020 | 2814 | 0.070 |
Why?
|
Case-Control Studies | 5 | 2023 | 22245 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2022 | 10263 | 0.070 |
Why?
|
Delphi Technique | 2 | 2021 | 892 | 0.070 |
Why?
|
Quality Improvement | 1 | 2021 | 3849 | 0.060 |
Why?
|
Immunoglobulin G | 2 | 2020 | 4559 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2021 | 4527 | 0.060 |
Why?
|
Blood Sedimentation | 2 | 2019 | 234 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1350 | 0.060 |
Why?
|
Physical Examination | 1 | 2010 | 1265 | 0.060 |
Why?
|
Chicago | 1 | 2024 | 255 | 0.060 |
Why?
|
Infant, Newborn | 4 | 2023 | 26388 | 0.050 |
Why?
|
Critical Care | 3 | 2021 | 2714 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 186 | 0.050 |
Why?
|
Software | 1 | 2016 | 4464 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10379 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2023 | 609 | 0.050 |
Why?
|
Crowding | 1 | 2023 | 142 | 0.050 |
Why?
|
Diagnostic Errors | 2 | 2021 | 1276 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13472 | 0.050 |
Why?
|
Running | 1 | 2006 | 488 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20129 | 0.050 |
Why?
|
Lymphadenitis | 1 | 2021 | 99 | 0.040 |
Why?
|
Skin | 1 | 2014 | 4498 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39283 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12061 | 0.040 |
Why?
|
Pain Measurement | 1 | 2010 | 3576 | 0.040 |
Why?
|
Subcutaneous Tissue | 1 | 2020 | 131 | 0.040 |
Why?
|
Conjunctivitis | 1 | 2021 | 153 | 0.040 |
Why?
|
Facial Muscles | 1 | 2020 | 159 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2021 | 325 | 0.040 |
Why?
|
Discriminant Analysis | 1 | 2020 | 222 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2023 | 517 | 0.040 |
Why?
|
Hospital Mortality | 1 | 2013 | 5337 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2019 | 137 | 0.040 |
Why?
|
Patient Readmission | 1 | 2013 | 3282 | 0.040 |
Why?
|
Interleukin-1 | 1 | 2023 | 1251 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18075 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.040 |
Why?
|
Thrombelastography | 1 | 2021 | 194 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 794 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4652 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2021 | 434 | 0.040 |
Why?
|
Platelet Count | 1 | 2021 | 784 | 0.040 |
Why?
|
Databases, Factual | 1 | 2013 | 8061 | 0.040 |
Why?
|
Family Characteristics | 1 | 2023 | 1001 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2023 | 923 | 0.040 |
Why?
|
Cytokines | 2 | 2023 | 7436 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2023 | 975 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2021 | 1606 | 0.040 |
Why?
|
Bacteriophages | 1 | 2020 | 382 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 36562 | 0.030 |
Why?
|
Ferritins | 1 | 2019 | 600 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2021 | 1866 | 0.030 |
Why?
|
Advisory Committees | 1 | 2021 | 796 | 0.030 |
Why?
|
Th1 Cells | 1 | 2021 | 1040 | 0.030 |
Why?
|
Dermatomyositis | 1 | 2019 | 259 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1186 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1574 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2421 | 0.030 |
Why?
|
Anticoagulants | 2 | 2021 | 4844 | 0.030 |
Why?
|
Mutation | 1 | 2020 | 30220 | 0.030 |
Why?
|
Hypotension | 1 | 2021 | 887 | 0.030 |
Why?
|
Virus Diseases | 1 | 2021 | 720 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1719 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2021 | 804 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2021 | 1069 | 0.030 |
Why?
|
Face | 1 | 2020 | 1029 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14643 | 0.030 |
Why?
|
Lung | 1 | 2013 | 10064 | 0.030 |
Why?
|
Autoantibodies | 1 | 2023 | 2115 | 0.030 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2021 | 1021 | 0.030 |
Why?
|
Biopsy | 2 | 2016 | 6778 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2038 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5302 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2021 | 1466 | 0.030 |
Why?
|
Reference Values | 1 | 2019 | 4913 | 0.020 |
Why?
|
Regression Analysis | 1 | 2021 | 6327 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2022 | 1945 | 0.020 |
Why?
|
Acute Disease | 1 | 2021 | 7240 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3198 | 0.020 |
Why?
|
Blood Platelets | 1 | 2021 | 2465 | 0.020 |
Why?
|
Biomedical Research | 1 | 2006 | 3458 | 0.020 |
Why?
|
Laryngoscopy | 1 | 2016 | 714 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2534 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3906 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9654 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2023 | 4784 | 0.020 |
Why?
|
Glycosylation | 1 | 2012 | 1100 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2019 | 2114 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5872 | 0.020 |
Why?
|
Joints | 1 | 2011 | 324 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 2763 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2021 | 4410 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2727 | 0.020 |
Why?
|
Middle Aged | 2 | 2021 | 223127 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3782 | 0.020 |
Why?
|
Aged | 1 | 2021 | 171234 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3068 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1691 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4428 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 6205 | 0.020 |
Why?
|
Internship and Residency | 1 | 2006 | 5944 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 21509 | 0.010 |
Why?
|
International Cooperation | 1 | 2011 | 1434 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26294 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3530 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6967 | 0.010 |
Why?
|